Question 1

What is the catalog number for Compound STOCK1N-54181?

Accepted Answer

The catalog number for Compound STOCK1N-54181 is T126940.

Question 2

Is Compound STOCK1N-54181 in stock?

Accepted Answer

Compound STOCK1N-54181 is currently made to order / not held in immediate stock. Contact us for lead time.

Question 3

Who manufactures Compound STOCK1N-54181?

Accepted Answer

Compound STOCK1N-54181 is manufactured by Molfinity.

Question 4

What is the estimated delivery time for Compound STOCK1N-54181?

Accepted Answer

Estimated delivery time for Compound STOCK1N-54181 is approximately 10 business day(s), depending on your location.

Question 5

What is the recommended incubation time for this antibody?

Accepted Answer

A suggested incubation time is provided in the recommended protocol on the datasheet, but may need adjusting depending on your sample type and detection system.

Question 6

What should I check when this product first arrives?

Accepted Answer

Inspect the package immediately for transportation damage, ice loss, leakage, or breakage. Report any issues right away with photos and your order reference; our specialists will determine whether the product is still usable or needs replacing.

Question 7

Does this cell line or biologic require a Material Transfer Agreement (MTA)?

Accepted Answer

Some products, including certain cell lines, plasmids, and tissue cultures, are subject to intellectual property terms and may require an MTA before we can ship. We’ll inform you in advance if this product requires one, and additional handling fees may apply.

Compound STOCK1N-54181

Product Specifications

Available Sizes

Frequently Asked Questions

Explore Other Products

Tau (MAPT) Rabbit Polyclonal Antibody

Glucose Transporter GLUT4 Recombinant Rabbit monoclonal Antibody

Benzhydryl 2-(3-benzyl-7-oxo-4-thia-2,6-diazabicyclo[3.2.0]hept-2-en-6-yl)-3-morpholinobut-2-enoate (E/Z mixture)

Polystyrene A NH₂

CD45RO (UCHL1 + T200/797), CF488A conjugate, 0.1mg/mL

OR1J4 Human Gene Knockout Kit (CRISPR)